Facebook
Instagram
Linkedin
Youtube
Start
News
Studio
Events
Newsletter
About BioStock
Contact us
Career
Search
BioStock
Start
News
Studio
Events
Newsletter
About BioStock
Contact us
Career
Home
Search
Abliva
-
search results
If you're not happy with the results, please do another search
Abliva leads the fight against mitochondrial disease
18 September, 2024
Abliva’s CEO: We are the leading programme in mitochondrial disease
26 August, 2024
Abliva’s CEO: “One step closer to a marketed medicine”
24 July, 2024
BioStock Global Forum 2024
3 June, 2024
Ablivas CEO: “We remain on track for the interim analysis early...
29 May, 2024
Abliva’s mission to become mitochondrial medicine powerhouse
8 April, 2024
Abliva’s CEO comments on the proposed capital raise
29 February, 2024
Abliva reaches enrollment goal
21 December, 2023
Abliva’s CEO: ”Orphan drug designation is great validation”
15 December, 2023
Abliva signs global license deal for NeuroSTAT
16 November, 2023
All sessions from BioStock Life Science Fall Summit 2023
30 October, 2023
Video from day 1 of BioStock Life Science Fall Summit 2023
26 October, 2023
Abliva’s VP of Clinical Operations on the screening achievement
18 October, 2023
Abliva increases awareness of mitochondrial diseases
19 September, 2023
Abliva receives FDA Fast Track designation
8 September, 2023
First patient dosed in Abliva’s Falcon study
30 June, 2023
Abliva’s presence is felt at Euromit
14 June, 2023
FDA grants Abliva’s NV354 Orphan Drug Designation
19 April, 2023
Abliva’s CEO about the phase II study
22 March, 2023
BioStock Investor Meeting starts today at 10.00
16 March, 2023
BioStock Investor Meeting 2023
10 February, 2023
Abliva recruits Vice President of Clinical Operations
10 February, 2023
Several biotech stocks surging during strong January
1 February, 2023
VILDA – new network for female leaders in life science
16 January, 2023
Amgen targets rare diseases with acquisition
15 December, 2022
The value of patent protection in life science
14 December, 2022
Abliva starts late-stage study with KL1333
12 December, 2022
Patient perspective in focus in Abliva’s phase II/III study
15 November, 2022
NLSDays: Interviews with 10 interesting companies
6 October, 2022
Raising awareness around patients with mitochondrial diseases
19 September, 2022
A new approach to mitochondrial diseases
10 August, 2022
Abliva secures funding to advance KL1333 into phase II/III
3 June, 2022
Abliva on the 200 MSEK financing round
1 June, 2022
CombiGene’s new project manager on a broadened pipeline
16 May, 2022
Celebrating IND approval Abliva eyes next step with KL1333
7 March, 2022
Abliva is ready for a pivotal year
3 February, 2022
Abliva on the IND-approval from FDA
15 December, 2021
FDA approves Abliva’s IND-application for KL1333
26 November, 2021
Abliva’s NV354 targets fatal paediatric disease
27 October, 2021
Join us for the BioStock Life Science Summit on October 20...
20 October, 2021
Raising awareness of mitochondrial diseases
23 September, 2021
Abliva’s NV354 to progress to clinical development
20 September, 2021
Q2 report shows strong clinical development for Abliva
24 August, 2021
Abliva’s CMO on the progress during H1
15 July, 2021
NeuroVive Pharmaceutical changes name to Abliva
5 July, 2021
Abliva’s newest board member sees potential in primary mitochondrial diseases
5 July, 2021
Abliva has strengthened its position during 2020
4 July, 2021
Abliva’s KL1333 development plan receives OK from FDA
4 July, 2021
New research supports Abliva’s KL1333 treatment strategy
4 July, 2021
Abliva is ready to start patient enrolment during autumn
4 July, 2021
Abliva accelerates development of KL1333
4 July, 2021
Abliva raise awareness of mitochondrial diseases
4 July, 2021
Abliva doses first patient in KL1333 study
3 July, 2021
Eventful Q3 paves way for Abliva’s main candidate KL1333
3 July, 2021
Big investment sign of great interest in mitochondrial diseases
2 July, 2021
Abliva’s KL1333 heading for phase II/III in 2021
2 July, 2021
Abliva raises 80 MSEK through directed share issue
2 July, 2021
Sprint Bioscience’s new CEO on the business model and cancer projects
1 July, 2021
Abliva’s CEO on the positive phase Ia/b results with KL1333
24 May, 2021
Abliva completes phase Ia/Ib study with KL1333
19 March, 2021
1
2
Page 1 of 2
